Bio-Path Holdings, Inc. (BPTH)

Oncology Corporate Profile

Stock Performance

2.3100
-0.1800

HQ Location

2626 South Loop
Houston, TX 77054

Company Description

Bio-Path is a biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path's lead product candidate, Liposomal Grb-2, is in a Phase I study for blood cancers and in preclinical studies for triple negative and inflammatory breast cancers. Bio-Path's second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.

Website: http://www.biopathholdings.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
prexigebersen / BP1001liposomal Grb2 antisenseAcute Myelogenous Leukemia (AML)II
prexigebersen / BP1001liposomal Grb2 antisenseChronic Myelogenous Leukemia (CML)II
prexigebersen / BP1002liposomal Bcl2LymphomaPreclinical
prexigebersen / BP1001liposomal Grb2 antisenseVarious cancer typesPreclinical

View additional information on product candidates here »

Source: http://www.biopathholdings.com/

Recent News Headlines

5/26/2017 06:17 am

5/26/2017 06:17 am

5/26/2017 06:17 am

5/11/2017 06:17 am

5/11/2017 12:17 am

5/11/2017 12:17 am

5/11/2017 12:17 am

5/4/2017 06:17 am

5/4/2017 06:17 am

5/4/2017 06:17 am

Bio-Path reports 4Q loss

3/15/2017 11:03 am

Bio-Path reports 4Q loss

3/15/2017 11:03 am

Bio-Path Holdings Reports Full Year 2016 Financial Results

3/15/2017 11:00 am

[GlobeNewswire] - HOUSTON, March 15, 2017-- Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid ...

Bio-Path Holdings to Present at the Oppenheimer 27th Annual Healthcare Conference

3/14/2017 12:00 pm

[GlobeNewswire] - HOUSTON, March 14, 2017-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic ...

Bio-Path Holdings Announces Rescheduled Date and Time of Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017

3/13/2017 12:00 pm

[GlobeNewswire] - HOUSTON, March 13, 2017-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic ...

Bio-Path Holdings to Present Data at the 2017 AACR Annual Meeting

3/10/2017 01:00 pm

[GlobeNewswire] - HOUSTON, March 10, 2017-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic ...

Bio-Path Holdings to Announce Fourth Quarter and Full Year 2016 Financial Results on March 14, 2017

3/9/2017 09:00 pm

[GlobeNewswire] - HOUSTON, March 09, 2017-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic ...

Bio-Path Holdings Appoints Dr. Craig Hooper to Scientific Advisory Board

2/21/2017 01:00 pm

[GlobeNewswire] - HOUSTON, Feb. 21, 2017-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid ...